Business Context and Reporting Period
This Form 8-K is a current report filed by Manhattan Pharmaceuticals, Inc. (not TG Therapeutics, Inc., as indicated in the metadata) on January 4, 2011, covering the event date of December 31, 2010. The filing addresses a change in the company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance updates and contains no financial statements or performance data.
Material Changes
The material change reported is the departure of a director:
- Malcolm Morville has retired and tendered his resignation from the Board of Directors, effective December 31, 2010.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future operations, risks, contingencies, or unusual items. The document focuses solely on the resignation of the director.
Key Facts for Investor Verification
- Verify the identity of the registrant as Manhattan Pharmaceuticals, Inc., noting the discrepancy with the provided metadata name.
- Confirm the effective date of Malcolm Morville's resignation as December 31, 2010.
- Check subsequent filings to determine if a replacement director was appointed to fill the vacancy.